Skip to main content
. 2021 Jun 11;12:652136. doi: 10.3389/fphys.2021.652136

FIGURE 3.

FIGURE 3

Individual (black lines) and median (red line) headache intensity after glibenclamide and placebo, n = 20. All participants received CGRP-infusion at 120 min. On glibenclamide-CGRP day 14 reported headache and on placebo-CGRP day 19 participants reported headache. We found no difference in headache incidence and intensity between glibenclamide-CGRP and placebo-CGRP day (P = 0.06).